316 related articles for article (PubMed ID: 26968976)
1. Predictors of Triptan Response in Pediatric Migraine.
Johnson HF; Goadsby PJ; Gelfand AA
Pediatr Neurol; 2016 May; 58():37-40. PubMed ID: 26968976
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
[TBL] [Abstract][Full Text] [Related]
3. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
4. Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy.
Lipton RB; Schmidt P; Diener HC
Headache; 2017 May; 57(5):756-765. PubMed ID: 28386945
[TBL] [Abstract][Full Text] [Related]
5. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
6. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
[TBL] [Abstract][Full Text] [Related]
7. Predictors of adherence to triptans: factors of sustained vs lapsed users.
Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
[TBL] [Abstract][Full Text] [Related]
8. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
[TBL] [Abstract][Full Text] [Related]
9. Triptans for Acute Migraine Headache: Current Experience With Triptan Use and Prescription Habits in a Tertiary Care Headache Outpatient Clinic: An Observational Study.
Fischer M; Frank F; Wille G; Klien S; Lackner P; Broessner G
Headache; 2016 Jun; 56(6):952-60. PubMed ID: 27091593
[TBL] [Abstract][Full Text] [Related]
10. Patterns of use and health expenses associated with triptans among adults with migraines.
Wu J; Noxon V; Lu ZK
Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
[TBL] [Abstract][Full Text] [Related]
11. Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients.
Eren OE; Gaul C; Peikert A; Gendolla A; Ruscheweyh R; Straube A
Sci Rep; 2020 Jul; 10(1):11382. PubMed ID: 32647152
[TBL] [Abstract][Full Text] [Related]
12. Cranial autonomic symptoms in pediatric migraine are the rule, not the exception.
Gelfand AA; Reider AC; Goadsby PJ
Neurology; 2013 Jul; 81(5):431-6. PubMed ID: 23897870
[TBL] [Abstract][Full Text] [Related]
13. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
Cady R; Martin V; Adelman J; Diamond M; Sajjan S; Hu XH
Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
[TBL] [Abstract][Full Text] [Related]
14. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
[TBL] [Abstract][Full Text] [Related]
15. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
[TBL] [Abstract][Full Text] [Related]
16. [Clinical use of triptans in the management of migraine].
Lantéri-Minet M
CNS Drugs; 2006; 20 Spec no.1():12-23. PubMed ID: 16841523
[TBL] [Abstract][Full Text] [Related]
17. Acute management of migraine.
Chowdhury D
J Assoc Physicians India; 2010 Apr; 58 Suppl():21-5. PubMed ID: 21049703
[TBL] [Abstract][Full Text] [Related]
18. Effects of switching acute treatment on disability in migraine patients using triptans.
Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
[TBL] [Abstract][Full Text] [Related]
19. Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity.
Akerman S; Karsan N; Bose P; Hoffmann JR; Holland PR; Romero-Reyes M; Goadsby PJ
Brain; 2019 Jan; 142(1):103-119. PubMed ID: 30596910
[TBL] [Abstract][Full Text] [Related]
20. Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study.
Viana M; Sances G; Terrazzino S; Zecca C; Goadsby PJ; Tassorelli C
Cephalalgia; 2021 Feb; 41(2):197-202. PubMed ID: 32955929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]